Abstract
We have investigated the use of the antibody MIB1 as a proliferative and prognostic marker in breast cancer and whether changes in proliferative activity could account for differences in prognosis of premenopausal women operated on during different phases of the menstrual cycle. MIB1 expression was strongly correlated with S-phase fraction and histological grade. There was no difference in MIB1 scores between different phases of the menstrual cycle. Both MIB1 score and timing of surgery correlated significantly with duration of survival, while the two together were even stronger predictors of overall survival. Women with slowly proliferating tumours surgically removed in the luteal phase had a very good prognosis, whereas women with rapidly proliferating tumours excised at other times of the cycle had a worse prognosis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cooper, L., Gillett, C., Smith, P. et al. Cell proliferation measured by MIB1 and timing of surgery for breast cancer. Br J Cancer 77, 1502–1507 (1998). https://doi.org/10.1038/bjc.1998.247
Issue Date:
DOI: https://doi.org/10.1038/bjc.1998.247
This article is cited by
-
Outcome Prediction of Pulmonary Metastasectomy Can Be Evaluated Using Metastatic Lesion in Osteosarcoma Patients
World Journal of Surgery (2013)
-
A New Ki-67 / E-Cadherin Cocktail Reduces Inter-observer Variation of the Calculated Proliferative Index
Pathology & Oncology Research (2013)
-
Prognostic factors in prostate cancer
Diagnostic Pathology (2006)
-
Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?
Diagnostic Pathology (2006)
-
Molecular pathology of Breast Cancer: Prognostic and predictive markers in this century and the next
Breast Cancer (1999)